4.75 USD
▲+0.37+3.26%
2026-08-03
市值
$29.39M
市盈率
—
EPS
-8.70
股息率
—
52 周区间
3.98 – 13.69
成交量
81.45K
Beta
2.26
目标价
56.29
52W 低 3.9852W 高 13.69
价格走势
公司简介
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea...